H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is one of the 11 Best Stocks to Buy for Investment.

On January 26, TheFly reported that H.C. Wainwright raised its price target on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) from $102 to $130 while maintaining its Buy rating. Swayampakula Ramakanth from H.C. Wainwright has increased the price target on MIRM twice in a span of two weeks.

Ramakanth’s price target revisions are based on Mirum’s bullish guidance for 2026. The analysts see 2026 to be a vital year for volixibat as clinical evaluation enters into two chronic immune-mediated cholestatic liver diseases. The analyst believes that volixibat could launch as early as the first half of 2027. The company expects the Volixibat VISTAS study in primary sclerosing cholangitis topline data in the second quarter of 2026, while enrollment for the study is expected to be completed in the second half of 2026.

Over the past six months, as of January 27, MIRM shares have skyrocketed over 91%. All 11 analysts covering Mirum Pharmaceuticals rate the stock a Buy, with the median price target set at $103, implying a slight upside of just under 4%. Ramakanth’s price target of $130 implies an upside potential of almost 31%.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a biopharmaceutical firm that engages in the development and commercialization of therapies for debilitating rare and orphan diseases.

While we acknowledge the potential of MIRM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best New Penny Stocks to Invest In and 13 Best Gold Mining Companies to Invest In Now.

Disclosure: None. This article is originally published at Insider Monkey.